IMM-H007, an adenosine derivative, is an activator of AMP-Activated Protein Kinase (AMPK). IMM-H007 is a potential drug for treating cardiac dysfunction. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 (ATP binding cassette subfamily a member 1) degradation and facilitates its cell-surface localization in macrophages, thereby promotes cholesterol efflux.
IMM-H007 reduces isoprenaline-induced Smad2/3 phosphorylation downstream of TGFβ1 and cardiac fibrosis via an AMPKα2-independent pathway, but the inhibition of TGFβ1 expression is AMPKα2-dependent.[4]
[1] Weipeng Ge, et al. Eur J Pharmacol. 2019 Aug 15;857:172442. [2] Jinjin Yu, et al. Toxicol Appl Pharmacol. 2019 Oct 15;381:114732. [3] LinZhang Huang, et al. J Lipid Res. 2015 May;56(5):986-97.